TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02351908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
Study: NCT03889470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NTG 1 MG/ML Injectable Solution
Description: administered after sheath placement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NTG 1 MG/ML Injectable Solution
Description: administered after sheath placement
Study: NCT00012181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02377713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK6640
Description: Single ascending dose administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending dose administration
Study: NCT04088474

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vigiis 101-LAB
Description: examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin was used as a placebo
Study: NCT01354106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Trauma
Description: Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.

Intervention type: DEVICE
Group type: OTHER
Intervention: Skin Trauma
Description: Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
Study: NCT01803841

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transradial coronary angiography and intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral coronary angiography and intervention
Study: NCT03972774

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET Stress Test
Description: Cardiac positron emission tomography (PET)/computed tomography (CT) and test-result dependent management

Intervention type: OTHER
Group type: OTHER
Intervention: Non-PET Medical Management
Description: Appropriate medical management without cardiac PET stress-imaging
Study: NCT00451841

Intervention type: DEVICE
Intervention: RTube Exhaled Breath Condensate Collection System
Description: Subjects breath through the device to collect exhaled breath condensate

Intervention type: DEVICE
Intervention: RTube Exhaled Breath Condensate Collection System
Description: Subjects breath through the device to collect exhaled breath condensate
Study: NCT03073460

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound examination
Description: This exam is performed at 40 weeks gestation
Study: NCT05595421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: See detail in arm/group descriptions regarding the intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: See detail in arm/group descriptions regarding the intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: See detail in arm/group descriptions regarding the intervention.
Study: NCT03837613

Intervention type: PROCEDURE
Intervention: tumor resection and neck dissection
Description: Surgical removal of the tumor with adequate safety margins. In addition to neck dissection to dissect the cervical lymph nodes.

Intervention type: PROCEDURE
Intervention: tumor resection and neck dissection
Description: Surgical removal of the tumor with adequate safety margins. In addition to neck dissection to dissect the cervical lymph nodes.
Study: NCT00976703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: weighted bag
Description: For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: leg taping
Description: For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
Study: NCT04722861

Intervention type: OTHER
Intervention: GVFQ-40
Description: GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons.

Intervention type: OTHER
Intervention: GVFQ-40
Description: GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons.
Study: NCT00975221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cinacalcet
Description: Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally following the same tiitration regimen as the experimental arm.
Study: NCT02818660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synachten
Description: To stimulate the adrenals to increase the cortisol Production as much as possible
Study: NCT03139838

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-Based Intervention A
Description: Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-Based Intervention A
Description: Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.
Study: NCT01364441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2952
Description: 3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
Study: NCT03139838

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-Based Intervention B
Description: Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-Based Intervention B
Description: Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.
Study: NCT02351440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: patients will be randomized to receive either duloxetine or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01364441

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosed in the same manner as ONO-2952
Study: NCT05654558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auxiliary cantilever intrusion arches on initial archwires
Description: Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine leveling and alignment
Description: Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
Study: NCT04275180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Argatroban plus standard medical treatment
Study: NCT03063970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Lycra Orthosis
Description: Dynamic lycra orthoses: made to measure fabric lycra compression gauntlets individually tailored to correct upper limb movement and positioning. Worn for eight hours per day but may be removed for therapy and washing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Rehabilitation
Description: Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
Study: NCT01089387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of bone marrow mononucleated cells
Description: Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.
Study: NCT00694564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl methionine
Description: S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
Study: NCT03063970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Rehabilitation
Description: Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
Study: NCT01284634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003 200 mg/day Dose
Description: GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003 400 mg/day Dose
Description: GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003 800 mg/day Dose
Description: GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
Study: NCT01271153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
Study: NCT03379779

Intervention type: DIAGNOSTIC_TEST
Intervention: 16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool
Description: We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
Study: NCT00645216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Subjects take CP-945,598 alone for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21
Study: NCT03895437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TOL-3021
Description: TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TOL-3021 Placebo
Description: TOL-3021 Placebo
Study: NCT02670538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsule one per day orally.
Study: NCT00785850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower
Study: NCT01732588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZ439 120mg PIB
Description: 120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg OZ439 caplet
Description: 120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120mg OZ439 caplet via Enterion capsule
Description: 120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
Study: NCT02670538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsule one per day orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule one per day orally.
Study: NCT00436579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of therapy complications
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of therapy complications
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03859375

Intervention type: OTHER
Intervention: microbial skin counts in the disinfection area after paints of skin disinfectants
Description: microbial skin counts in the disinfection area after 2 and 3 paints of skin disinfectants (chlorhexidine in alcohol \[CHX\] and povidone iodine in alcohol \[PI\])

Intervention type: OTHER
Intervention: microbial skin counts in the disinfection area after paints of skin disinfectants
Description: microbial skin counts in the disinfection area after 2 and 3 paints of skin disinfectants (chlorhexidine in alcohol \[CHX\] and povidone iodine in alcohol \[PI\])
Study: NCT02555488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: MB and diode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: diode laser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene blue
Description: Methylene blue and diode laser was used
Study: NCT05217069

Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU
Description: 400 mg/m2 (i.v. bolus) 2400 mg/m2 (i.v. 46h)

Intervention type: DRUG
Group type: OTHER
Intervention: Folinic Acid
Description: 400mg/m2

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: 180 mg/m2

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: 400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w

Intervention type: DRUG
Group type: OTHER
Intervention: Avelumab
Description: 10mg/kg IV (day 1 q2w)
Study: NCT01705275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8539
Description: ONO-8539

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to ONO-8539 tablet but without active ingedient
Study: NCT02621502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa variety 1
Description: On the intervention day, the volunteers will consume the Quinoa Variety 1.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa variety 2
Description: On the intervention day, the volunteers will consume the Quinoa Variety 2.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa variety 3
Description: On the intervention day, the volunteers will consume the Quinoa Variety 3.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa variety 4
Description: On the intervention day, the volunteers will consume the Quinoa Variety 4.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
Study: NCT01882595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulization through the tracheostomy
Description: Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulization through the mouth
Description: Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
Study: NCT03220945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Receive yoga instruction
Study: NCT01785628

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sarcosine Capsule
Description: Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo is dextrin composition.
Study: NCT01997320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy resistance exercise and nutrition
Description: Heavy resistance exercise of the lower extremities three times weekly for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition supplement
Description: Two daily administrations of nutrient supplementation, each containing 20g of milk protein.
Study: NCT00767104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silk like Pillowcase
Description: sleep on silk-like pillowcase each night

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cotton Pillowcase
Description: Sleep on placebo cotton pillowcase each night
Study: NCT02890914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transvaginal Ultrasound Educational DVD
Description: American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®
Study: NCT00321334

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy+Surgery
Description: Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles